Atopic Dermatitis in Children: Upadacitinib vs. Dupilumab

We are studying whether upadacitinib is as safe and effective as dupilumab for children aged 2 to under 12 with moderate to severe atopic dermatitis. This trial aims to find better treatment options for young patients.

>2 years >20 visits Confirmation phase (III)No Placebo Cost Reimbursement Partially Remote Standard Medicines Oral InjectionAllergologyDermatologyPediatrics

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Dupixent

Dupixent is a medicine used to treat eczema and certain asthma symptoms.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dupilumab

Dupilumab is a substance that reduces allergic inflammation to treat moderate-to-severe eczema, some asthma, and nasal polyps.

Upadacitinib

Upadacitinib is a substance that reduces inflammation by targeting the immune system and is used for certain autoimmune conditions.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Medical University Of Graz

Universitaetsklinik fuer Dermatologie und Venerologie

Graz, Austria

Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

Universitaetsklinik fuer Kinder- und Jugendheilkunde

Salzburg, Austria

Medical University Of Vienna

Universitaetsklinik fuer Kinder- und Jugendheilkunde

Vienna, Austria

Sponsor: AbbVie Deutschland GmbH & Co. KG

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.